
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences Ltd demonstrates a promising outlook with its drug candidate Brepocitinib (Brepo), which has shown a significant mean total improvement score of 46.5 at week 52, indicating its potential as a highly effective treatment option. The company’s strategic focus on convenient once-daily (QD) dosing of Brepo, compared to the cumbersome intravenous immunoglobulin (IVIg) therapy, positions it favorably in a market with an existing global sales record of approximately $500 million. This combination of competitive efficacy results and improved patient compliance suggests strong market demand for Brepo and supports a positive perspective on Roivant Sciences' overall financial health and growth potential.
Bears say
Roivant Sciences Ltd. faces significant challenges due to the failure of multiple drug candidates in clinical trials, notably the IMVT assets and brepocitinib across several indications, which severely undermines investor confidence in its pipeline. The repeated failures revealed in the reports indicate a troubling trend that raises concerns about the company's ability to develop and commercialize viable treatments, further jeopardizing its financial stability. Consequently, these clinical setbacks could adversely impact revenue growth prospects and overall market performance, leading to a potentially negative outlook for the stock.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares